Evaluation of Serum Interleukin-6 Levels in the Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Case-Control Studies

Hamidreza Omrani1, Sayed Vahid Jasemi2, Masoud Sadeghi3, Sima Golmohamadi1*

1Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Department of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Abstract

AIM: The purpose of this meta-analysis was the assessment of the serum IL-6 levels in the renal transplant recipients compared to the healthy controls.

MATERIAL AND METHODS: Four databases including PubMed, Web of Science, Scopus, and Cochrane Library were searched up to July 2018 without language restriction. The quality of studies was evaluated using the Newcastle-Ottawa scale (NOS). A continuous random-effects meta-analysis was used by RevMan 5.3 using the mean difference (MD) and 95% confidence intervals (CIs). Also, a regression model was done by Comprehensive Meta-Analysis version 2 (CMA v2).

RESULTS: Out of 615 studies identified in the databases, 15 studies included and analysed in the meta-analysis. The studies were reported from 1994 to 2018. The meta-analysis included 1035 renal transplant recipients and 682 healthy controls. The pooled MD of the serum IL-6 levels in the transplant recipients compared to the healthy controls was 3.25 pg/mL [95%CI: 2.17, 4.32; P = 0.00001; I² = 98% (P < 0.00001)]. Meta-regression analysis showed that one of the reasons of heterogeneity is the year of publication (Correlation coefficient (r) = 0.208, p-value = 0.0002).

CONCLUSION: An elevated serum IL-6 level in the renal transplant recipients compared to the healthy controls showed that the serum level of this marker could be used for the evaluation of inflammation in ESRD patients undergoing renal transplantation.

Introduction

Chronic kidney disease (CKD) is the usual name for various disorders impacting renal structure and functions [1]. The incidence of cardiovascular disease in patients of end-stage renal disease (ESRD) is 10–20-fold that in the general population [2]. Renal transplantation (RT) is the treatment of choice for ESRD patients [3], [4]. Acute rejection is a common complication after RT and is associated with reduced graft survival [5]. Cardiovascular and cerebrovascular diseases are the leading causes of death following renal transplantation [6], [7] that the main underlying reason is inflammation [7]. Inflammation is generally controlled by following changes in concentrations of C-reactive protein (CRP), cytokines, and chemokines [8]. Interleukin-6 (IL-6) is reportedly responsible for acute complications in patients with ESRD such as fever, headache, and hypotension [9]. This cytokine is also a reliable marker of disease severity and inflammatory organ injury in rheumatoid arthritis [10] and oral lichen planus [11]. Therefore, it has been found to act as both a pro-inflammatory and anti-inflammatory cytokine [12]. Also, the serum IL-6 levels increase depending on the reduction of renal function.
The meta-analysis aimed to assess the serum IL-6 levels in the renal transplant recipients compared to the healthy controls.

Material and Methods

The meta-analysis created according to a guideline for the preferred reporting items for systematic review and meta-analysis (PRISMA) literature search [14].

The research protocol was supported by the Ethics Committee of Kermanshah University of Medical Sciences, Kermanshah, Iran (Ethical code: IR.KUMS.REC.1396.597). A comprehensive search was used with the databases of PubMed, Web of Science, Scopus, and Cochrane Library up to July 2018. A combination of terms "kidney transplantation" or "renal transplantation" or "renal transplant" or "serum interleukin-6" and "IL-6" was used in the search without language restriction. The studies were selected for evaluation of the serum IL-6 levels in the renal transplant recipients compared with the healthy controls. The studies included in this meta-analysis had to: (I) use a case-control design; (II) report the serum IL-6 levels in the renal transplant recipients (III) report the controls without renal transplantation and any systematic disease (the healthy controls). Before transplantation, the more renal transplant recipients were on renal replacement therapy (pretransplant dialysis) and had immunosuppressive treatment.

One reviewer (M.S) searched the articles and then selected the relevant publications and other authors reviewed them independently. We applied a regular protocol and recording information for data extraction from each publication including the first author’s name, the year of publication, the country which the study was reported, number/the mean age/male (%) of the cases and healthy controls, immunosuppressive regimen, measured method of IL-6, level, and transplantation evolution.

The quality of studies was evaluated using the Newcastle-Ottawa scale (NOS) [15], in which the maximum total score is 9 for the case-control study. The quality evaluation was done by one author (M.S) for each study.

To compare serum IL-6 levels in the renal transplant recipients compared with the healthy controls, a continuous random-effects meta-analysis was done by Review Manager 5.3 (RevMan 5.3, The Cochrane Collaboration, Oxford, United Kingdom) using the mean difference (MD) and 95% confidence intervals (CIs). Heterogeneity among studies was evaluated with the Q, and the I² statistic and results were defined as heterogeneous for P < 0.10 or I² > 50% [16] and P-value (2-sided) < 0.05 was estimated statistically significant in the meta-analysis study. Also, the publication bias was estimated by funnel plot using Begg’s and Egger’s tests. The unit of measurement of IL-6 levels was pg/mL. The meta-regression analysis is a technique used to evaluate heterogeneity between the studies. This statistical approach determines whether there is a significant association between the study period and the pooled MD of the serum IL-6 levels. A regression model by Comprehensive Meta-Analysis version 2 (CMA v2) was done with the p-value and regression coefficient (r) to evaluate the strength of this association.

Results

Out of 615 studies identified in the databases, after excluding duplicate studies, 344 studies were screened that 312 studies were excluded. Out of 32 studies that their full-texts were assessed for eligibility, 17 studies were removed with the reasons (Figure 1). At last, 15 studies included and analysed in the meta-analysis.

The features of 17 studies that have been included in the meta-analysis are shown in Table 1. The studies were reported from 1994 to 2018. Three studies [17], [18], [19] were reported from Poland, two
The mean age, male percentage, immunosuppressive regimens, and measured method of IL-6 level are shown in Table 1.

Table 1: Characteristics of the studies included in the meta-analysis (n = 15)

| First author, year | Selection | Comparability | Outcome | Total score |
|--------------------|-----------|---------------|---------|-------------|
| Nickerson, 1994 [21] | 2 | 0 | 2 | 4 |
| Waiser, 1997 [22] | 2 | 0 | 2 | 4 |
| Preston, 2002 [8] | 2 | 0 | 2 | 4 |
| Malan Borel, 2003 [23] | 3 | 1 | 2 | 6 |
| Lauzurica, 2005 [24] | 3 | 0 | 2 | 5 |
| Malyszko, 2006 [17] | 3 | 1 | 2 | 6 |
| Malyszko, 2008 [18] | 3 | 2 | 2 | 7 |
| Shagman, 2010 [25] | 3 | 1 | 2 | 6 |
| Malyszko, 2013 [19] | 2 | 0 | 2 | 4 |
| Sonkar, 2013 [26] | 3 | 2 | 2 | 7 |
| Xue, 2014 [5] | 3 | 2 | 2 | 7 |
| Colak, 2015 [20] | 4 | 2 | 2 | 8 |
| AvciÇiçek, 2016 [7] | 3 | 0 | 2 | 5 |
| Eskandari Naj, 2017 [3] | 2 | 2 | 2 | 6 |
| Argani, 2018 [27] | 3 | 2 | 2 | 7 |

One star if two groups matched via age and another star if two groups matched via sex or body mass index (BMI).

Figure 2 shows the funnel plot of studies entered to the analysis. Egger's test (p-value (2-tailed) = 0.042) reveal, but and Begg’s test (p-value (2-tailed) = 0.067) didn’t reveal a significant sign of publication bias between the involved studies.

Figure 3 shows the funnel plot of random-effects analysis that the pooled MD of the serum IL-6 levels in the transplant recipients compared to the healthy controls was 3.25 pg/mL [95% CI: 2.17, 4.32; P < 0.00001; I² = 98% (P < 0.00001)]. Therefore, the serum IL-6 level in the transplant recipients was significantly higher than the healthy controls.

Table 2: Quality ratings for the studies included by Newcastle-Ottawa quality assessment scale (n = 15)

| First author, year | Selection | Comparability | Outcome | Total score |
|--------------------|-----------|---------------|---------|-------------|
| Nickerson, 1994 [21] | 2 | 0 | 2 | 4 |
| Waiser, 1997 [22] | 2 | 0 | 2 | 4 |
| Preston, 2002 [8] | 2 | 0 | 2 | 4 |
| Malan Borel, 2003 [23] | 3 | 1 | 2 | 6 |
| Lauzurica, 2005 [24] | 3 | 0 | 2 | 5 |
| Malyszko, 2006 [17] | 3 | 1 | 2 | 6 |
| Malyszko, 2008 [18] | 3 | 2 | 2 | 7 |
| Shagman, 2010 [25] | 3 | 1 | 2 | 6 |
| Malyszko, 2013 [19] | 2 | 0 | 2 | 4 |
| Sonkar, 2013 [26] | 3 | 2 | 2 | 7 |
| Xue, 2014 [5] | 3 | 2 | 2 | 7 |
| Colak, 2015 [20] | 4 | 2 | 2 | 8 |
| AvciÇiçek, 2016 [7] | 3 | 0 | 2 | 5 |
| Eskandari Naj, 2017 [3] | 2 | 2 | 2 | 6 |
| Argani, 2018 [27] | 3 | 2 | 2 | 7 |
Meta-regression analysis identified a significant statistical relationship between the pooled MD of serum IL-6 levels in the renal transplant recipients compared with the healthy controls and the year of publication. This means that one of the reasons for heterogeneity is the year of publication (Correlation coefficient (r) = 0.208, p-value = 0.00002). Significant positive correlation showed that there was an increase in the MD of the serum IL-6 with time (Figure 4).

Discussion

The elevated serum IL-6 levels in the renal transplant recipients compared to the healthy controls have been shown in this meta-analysis study. The Th1 cytokine pattern is generally related to the rejection of the transplantation; a Th2 cytokine pattern may lead to transplant tolerance and stable graft survival. [13]. Inflammation is the most important underlying mechanism in cardiovascular disease and other systemic diseases [1]. Increased IL-6 leads to chronic inflammatory conditions such as the synthesis of acute phase proteins like CRP, hypercoagulability and accelerated atherosclerosis. [7], [28], [29], [30], [31] that can cause to the loss of renal function [7]. Also, some mechanisms including volume overload and oxidative stress can cause the usual increase in inflammatory symptoms (including IL-6) [32].

Serum levels of IL-6 increased significantly after renal transplantation [33]. The results received show an obvious relationship within the serum levels of IL-6 and graft rejection [23]. Levels of IL-6 have been greatly reduced in desirable evolution and raised with increasing renal failure. Therefore, the level of IL-6 can be used as an indicator of graft evolution and as a prerequisite for proper evaluation of renal biopsy [23]. The changes in the serum levels of IL-6 in transplanted patients can lead to several factors that affect the production of cytokines. Also, IL-6 may act a function in the close correlation between the high incidence of inflammation, cardiovascular disease, and malnutrition in HD patients [34]. CRP elevation may only represent the end stage of substantial inflammation, and other inflammatory markers may be more sensitive indicators of early inflammation injury, almost in HD patients [8]. Therefore, levels of CRP can correlate with IL-6 levels [9]. Serum levels of IL-6 in HD patients are significantly higher than in renal transplant recipients [20], [35]. The injury to the endothelium might trigger the release of IL-6 in renal transplant recipients [26]. This increase in IL-6 could be the result of increased activation of nuclear factor-kappa B, which is an inducible transplantation factor necessary for the activation of multiple important inflammatory cytokine genes like to the IL-6 gene [36]. 1) Pretransplant dialysis in the recipients. 2) Different immunosuppressive treatment in the recipients. 3) Differences in the measured method of IL-6 levels. 4) The sample size was small in some studies. 5) There was high heterogeneity in the analysis. 6) Low quality of more studies. Therefore, these limitations cause a bias between the studies.

In conclusion, about the limitations, there was an elevated serum IL-6 level in the renal transplant recipients compared to the healthy controls. The results may indicate potential usefulness of the serum level of this marker as an indicator of immunologic risk and can be used for the evaluation of inflammation in ESRD patients undergoing renal transplantation. HRO and SG conceptualised this study, designed the methodology for data collection, collected and analysed the data, and wrote the manuscript. SVJ and MS extensively supported the development of the study concept, data analysis, and the writing, editing and finalising of the manuscript. All authors read and approved the final manuscript.

References

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1-150.

2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovas¬cular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13):1285-95. https://doi.org/10.1056/NEJMoa041365 PMid:15385655

3. Eskandari Naji H, Ghorbanihagho A, Argani H, Raisi S, Safa J, Ailezaei AH, et al. Serum sTWEAK and PGF-23 Levels in Hemodialysis and Renal Transplant Patients. Int J Organ Transplant Med. 2017; 8(2):110-116. PMid:28828171 PMCid:PMC5549008

4. Palkoci B, Vojtko M, Fialová J, Osinová D, Lačiaková M. Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience. Int J Organ Transplant Med. 2018; 9(1):1-9. PMid:29531641 PMCid:PMC5839624

5. Harada KM, Mandra-Sampaio EL, de Sandes-Freitas TV, Felipe CR, Park SI, Pinheiro-Machado PG, et al. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc. 2009; 41(9):3867-70. https://doi.org/10.1016/j.transproceed.2009.04.013 PMid:19917364
6. Xue D, He X, Zhou C. Serum hepcidin level correlates with hyperlipidemia status in patients following allograft renal transplantation. Transplant Proc. 2014; 46(1):156-9. https://doi.org/10.1016/j.transproceed.2013.06.020 PMid:24507043

7. Avci Çiçek E, Rota S, Dursun B, Kavalcı E. Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients. Ren Fail. 2016; 38(1):35-9. https://doi.org/10.3109/0886022X.2015.1107823 PMid:26627016

8. Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, et al. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron. 2002; 92(4):817-23. https://doi.org/10.1159/000060546 PMid:12399626

9. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis. 2000; 35:611-6. https://doi.org/10.1053/ajkd.2000.22566

10. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. Effects of erythropoietin on erythropoiesis in patients with end-stage renal disease. Ren Fail. 2015; 37(1):45-54. https://doi.org/10.3109/0886022X.2015.1107823 PMid:26627016

11. Malyszko J, Malyszko JS, Pawlak K, Głowinska I, Malyszko M. Resistin, a new adipokine, is related to inflammation and renal function in patients with chronic kidney disease. Nephrol Dial Transplant. 1997; 12(4):753-9. https://doi.org/10.1093/ndt/12.4.753 PMid:9141007

12. Malan Borel I, Racca A, Garcia MI, Bialet A, Quiroga F, Soutullo A, et al. Gammadelta T cells and interleukin-6 levels could provide information regarding the progression of human renal allograft. Scand J Immunol. 2003; 58(1):99-105. https://doi.org/10.1046/j.1365-2956.2003.01275.x PMid:12828564

13. Rumjon A, Sarafidis P, Brincat S, Musto R, Malyszko J, Bansal SS, et al. Serum hemoglobin and hepcidin levels in chronic kidney disease. Am J Nephrol. 2012; 35(3):295-304. https://doi.org/10.1159/000336528 PMid:22398782